Immunohistochemical Expression of Melanocytic Antigen PNL2, Melan A, S100, and PGP 9.5 in Equine Melanocytic Neoplasms

The immunoreactivity of PNL2, Melan A, and protein gene product (PGP) 9.5 was compared with that of S100 protein in 50 formalin-fixed, paraffin-embedded equine melanocytic neoplasms. PNL2, PGP 9.5, and S100 protein were detected in all 50 neoplasms; none expressed Melan A. PNL2 was not expressed in...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary pathology 2014-01, Vol.51 (1), p.161-166
Main Authors: Ramos-Vara, J. A., Frank, C. B., DuSold, D., Miller, M. A.
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal
Biomarkers, Tumor - metabolism
Cross Reactions
Horses
Immunohistochemistry - veterinary
MART-1 Antigen - metabolism
Melanoma - diagnosis
Melanoma - metabolism
Melanoma - veterinary
Melanoma-Specific Antigens - metabolism
Neoplasm Proteins - metabolism
S100 Proteins - metabolism
Sensitivity and Specificity
Skin Neoplasms - diagnosis
Skin Neoplasms - metabolism
Skin Neoplasms - veterinary
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The immunoreactivity of PNL2, Melan A, and protein gene product (PGP) 9.5 was compared with that of S100 protein in 50 formalin-fixed, paraffin-embedded equine melanocytic neoplasms. PNL2, PGP 9.5, and S100 protein were detected in all 50 neoplasms; none expressed Melan A. PNL2 was not expressed in 62 nonmelanocytic tumors (equine sarcoids, schwannomas, carcinomas, sarcomas, endocrine tumors, sex-cord stromal tumors, germ cell tumors, and leukocytic tumors) or in normal tissues other than epidermis. In summary, antibody PNL2 is a sensitive marker of equine melanocytic neoplasms and is more specific than S100 protein or PGP 9.5. In contrast, the monoclonal antibody to Melan A did not react with any of the equine melanomas.
ISSN:0300-9858
1544-2217
DOI:10.1177/0300985812471545